World's Best Scientists 2026 revealed!
Award Badge
Best Female Scientists
2025

D-Index & Metrics

Best Female Scientists

D-Index
108
Citations
38658
World Ranking
986
National Ranking
601

Medicine

D-Index
110
Citations
39619
World Ranking
5618
National Ranking
3022

Research.com Recognitions

  • 2025 - Research.com Best Female Scientists Award
  • 1984 - Fellow of the American Statistical Association (ASA)

Overview

Kathleen R. Lamborn is affiliated with the University of California, San Francisco in the United States. Their research spans several fields including medicine, biochemistry, genetics, molecular biology, and mathematics, reflecting an interdisciplinary approach. Within these fields, the scientist has contributed specifically to genetics, cancer research, and modeling and simulation.

The main topics of their work concentrate on glioma diagnosis and treatment, cancer genomics and diagnostics, and mathematical biology related to tumor growth. These focus areas illustrate a blend of clinical and computational strategies aimed at understanding and addressing cancer progression.

Among their recent scholarly contributions is the paper titled "Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02", published in Neuro-Oncology Advances in 2020. This work has been cited 21 times, highlighting engagement within the oncology research community.

Frequent co-authors who have collaborated with Kathleen R. Lamborn include:

  • Huanwen Chen
  • John G. Kuhn
  • Lauren E. Abrey
  • Lisa M. DeAngelis
  • Frank S. Lieberman

The pattern of publication venues shows a focus on Neuro-Oncology Advances, where the scientist has published at least one paper.

Kathleen R. Lamborn was awarded the title of Fellow of the American Statistical Association (ASA) in 1984. This recognition indicates a significant contribution to the field of statistical science.

Best Publications

  • Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

    Patrick Y. Wen;David R. Macdonald;David A. Reardon;Timothy F. Cloughesy

  • Role of Extent of Resection in the Long-Term Outcome of Low-Grade Hemispheric Gliomas

    Justin S. Smith;Edward F. Chang;Kathleen R. Lamborn;Susan M. Chang

  • Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme

    Yu Liang;Maximilian Diehn;Nathan Watson;Andrew W. Bollen

  • Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome.

    G E Keles;K R Lamborn;M S Berger

  • Prognostic factors for survival of patients with glioblastoma: Recursive partitioning analysis

    Kathleen R. Lamborn;Susan M. Chang;Michael D. Prados

  • Seizure characteristics and control following resection in 332 patients with low-grade gliomas

    Edward F. Chang;Matthew B. Potts;G. Evren Keles;Kathleen R. Lamborn

  • Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib

    Daphne A. Haas-Kogan;Michael D. Prados;Tarik Tihan;David A. Eberhard

  • Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme.

    Penny K. Sneed;Paul R. Stauffer;Michael W. McDermott;Chris J. Diederich

  • Radiosurgery for brain metastases: is whole brain radiotherapy necessary?

    Penny K Sneed;Kathleen R Lamborn;Julie M Forstner;Michael W McDermott

  • Intraoperative subcortical stimulation mapping for hemispherical perirolandic gliomas located within or adjacent to the descending motor pathways: evaluation of morbidity and assessment of functional outcome in 294 patients.

    G Evren Keles;David A Lundin;Kathleen R Lamborn;Edward F Chang

  • Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08

    Patrick Y. Wen;W. K Alfred Yung;Kathleen R. Lamborn;Patricia L. Dahia

  • Transsphenoidal Microsurgery for Growth Hormone-Secreting Pituitary Adenomas: Initial Outcome and Long-Term Results

    A Abosch;J B Tyrrell;K R Lamborn;L T Hannegan

  • Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

    Susan M. Chang;Patrick Wen;Timothy Cloughesy;Harry Greenberg

  • Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas.

    Kathleen R. Lamborn;W. K.Alfred Yung;Susan M. Chang;Patrick Y. Wen

  • Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results.

    Gary D. Hammer;J. Blake Tyrrell;Kathleen R. Lamborn;Carol B. Applebury

  • Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

    Michael D. Prados;Susan M. Chang;Nicholas Butowski;Rebecca DeBoer

  • Results of the double-blind, randomized, multicenter, phase III clinical trial of thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation

    Osama O. Gaber;M. Roy First;Raymond J. Tesi;Robert S. Gaston

  • A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy

    Jeffrey J. Raizer;Lauren E. Abrey;Andrew B. Lassman;Susan M. Chang

  • Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients.

    Martha L. Simmons;Kathleen R. Lamborn;Michelle Takahashi;Pengchin Chen

  • Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors

    Igor Vivanco;H. Ian Robins;Daniel Rohle;Carl Campos

Frequent Co-Authors

Michael D. Prados
Michael D. Prados University of California, San Francisco
Susan M. Chang
Susan M. Chang University of California, San Francisco
William M. Wara
William M. Wara Kaiser Permanente
Mitchel S. Berger
Mitchel S. Berger University of California, San Francisco
David A. Larson
David A. Larson University of California, San Francisco
Penny K. Sneed
Penny K. Sneed University of California, San Francisco
Michael W. McDermott
Michael W. McDermott University of California, San Francisco
Patrick Y. Wen
Patrick Y. Wen Harvard University
Timothy F. Cloughesy
Timothy F. Cloughesy University of California, Los Angeles
Lisa M. DeAngelis
Lisa M. DeAngelis Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative or complementary healthcare degrees can open up diverse career opportunities for those interested in the medical field. Many students consider flexible, affordable online programs as a pathway to start or advance their careers without putting their lives on hold.

For those drawn to the business side of healthcare, researching healthcare administration degree cost can help you find programs that fit your budget while building valuable leadership skills. If you’re aiming higher, the cheapest mha programs online healthcare provide opportunities for advanced credentials in administration and management roles.

Clinical professionals interested in leadership or specialized practice might explore the best dnp programs online. These programs offer flexibility and advanced education for nurses wanting to reach the top of their field. Similarly, those looking to become pharmacists can benefit from the convenience and affordability of an online pharmacy degree.

Each of these online pathways provides unique benefits and can be a smart stepping stone toward a rewarding career in healthcare.

Best Scientists Citing Kathleen R. Lamborn

Trending Scientists

Recently Published Articles